Patents by Inventor Afzal Khan
Afzal Khan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240104483Abstract: Disclosed are methods and systems for converting data from an external system to data to be used by an internal system. For instance, a method may include receiving at least one user selection from a list of domains for executing at least one task, determining one or more data requirements corresponding to the at least one user selection, in response to determining the one or more data requirements, retrieving data from one or more external systems, converting the retrieved data based on the one or more data requirements, the converting including extracting data from the retrieved data based on the one or more data requirements, validating the extracted data, the validating including determining that the extracted data meets or exceeds a primary data requirement threshold, and outputting the validated extracted data to a data model for use by an internal system to execute the at least one task.Type: ApplicationFiled: September 28, 2022Publication date: March 28, 2024Inventors: Kalimulla Khan, Srihari Jayathirtha, Wade Lindsey, Afzal Hussaini Wiquar, Venkata Pradeep Kolla, Krishna Pillutla
-
Patent number: 10072005Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.Type: GrantFiled: January 19, 2018Date of Patent: September 11, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Andrew Payne, Jose Luis Castro Pineiro, Louise Michelle Birch, Afzal Khan, Alan James Braunton, James Edward Kitulagoda, Motohiro Soejima
-
Publication number: 20180208593Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.Type: ApplicationFiled: January 19, 2018Publication date: July 26, 2018Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Andrew Payne, Jose Luis Castro Pineiro, Louise Michelle Birch, Afzal Khan, Alan James Braunton, James Edward Kitulagoda, Motohiro Soejima
-
Patent number: 9926312Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.Type: GrantFiled: September 30, 2014Date of Patent: March 27, 2018Assignee: Eisai R&D Management Co., Ltd.Inventors: Andrew Payne, Jose Luis Castro Pineiro, Louise Michelle Birch, Afzal Khan, Alan James Braunton, James Edward Kitulagoda, Motohiro Soejima
-
Publication number: 20170342429Abstract: The present invention lies in the field of plant protection, in particular in the field of controlling plant pests and pathogens that affect plants. The present invention relates to a plant comprising a plastid comprising a double-stranded RNA (dsRNA) capable of silencing at least one target gene of a pest of a plant or of an agent causing a disease of a plant. The present invention further relates to such a transplastomic plant, wherein said dsRNA comprises two (separate) complementary single-stranded RNA strands. The present invention further relates to a plastid as comprised in the plant of the invention and to a plant cell comprising said plastid. Moreover, the present invention relates to a method of producing a plant of the invention and to a method of controlling a pest of a plant or a plant disease-causing agent or of protecting a plant from said pest or agent.Type: ApplicationFiled: December 18, 2015Publication date: November 30, 2017Applicant: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.Inventors: Ralph Bock, Jiang Zhang, David G. Heckel, Sher Afzal Khan
-
Patent number: 9446269Abstract: A system and method for fire suppression proactively identifies persons present, during a fire, in a fire suppressant release area. The persons are identified using an electronic monitoring system. An fire suppression system using a suppressant that is effective but unsafe for humans is put into service only if no person is detected. In situations where a person is present, an alternate fire suppressant is released that is safe for humans.Type: GrantFiled: December 17, 2012Date of Patent: September 20, 2016Assignee: General Electric CompanyInventors: Naseer Shaik, Pritesh Kasliwal, Mohammed Afzal Khan
-
Publication number: 20160244445Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.Type: ApplicationFiled: September 30, 2014Publication date: August 25, 2016Inventors: Andrew Payne, Jose Luis Castro Pineiro, Louise Michelle Birch, Afzal Khan, Alan James Braunton, James Edward Kitulagoda, Motohiro Soejima
-
Publication number: 20150275095Abstract: An apparatus and methodology for storing bitumen froth comprising a fluidized bottom, froth first feed holding tank for maintaining effective tank capacity while reducing overall solid bed build up at side walls and minimizing sloughing of solids to the froth discharge outlet. Froth is fed to the tank through one or more feed inlets located between the froth outlet and side walls for fluidizing settling solids. The feed inlets urge solids to settle in sub-beds about the feed inlets, the height of which that manifests adjacent the side walls being less that some design threshold height; if not, then successive feed inlets are located between the side walls and the precious feed inlets to build further sub-beds that have a height at the wall that is less than the threshold height.Type: ApplicationFiled: March 27, 2014Publication date: October 1, 2015Applicant: TOTAL E&P CANADA LTD.Inventors: William Nicholas GARNER, Saba MOETAMED-SHARIATI, Mohammad Afzal KHAN, Wei Y. ZHANG
-
Publication number: 20150094328Abstract: 4-Azaindole derivatives which are modulators of muscarinic acetylcholine receptor (mAChR) M1 and which may be effective for the prevention or disease modifying or symptomatic treatment of cognitive deficits associated with neurological disorders such as Alzheimer-type dementia (AD) or dementia with Lewy bodies (DLB), and a pharmaceutical composition comprising a 4-azaindole derivative as an active ingredient.Type: ApplicationFiled: September 30, 2014Publication date: April 2, 2015Inventors: Andrew Payne, Jose Luis Castro Pineiro, Louise Michelle Birch, Afzal Khan, Alan James Braunton, James Edward Kitulagoda, Motohiro Soejima
-
Patent number: 8946210Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: December 21, 2011Date of Patent: February 3, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Patent number: 8946211Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: March 14, 2013Date of Patent: February 3, 2015Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Yoichi Kita, Kunitoshi Takeda, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20140166319Abstract: A system and method for fire suppression proactively identifies persons present, during a fire, in a fire suppressant release area. The persons are identified using an electronic monitoring system. An fire suppression system using a suppressant that is effective but unsafe for humans is put into service only if no person is detected. In situations where a person is present, an alternate fire suppressant is released that is safe for humans.Type: ApplicationFiled: December 17, 2012Publication date: June 19, 2014Applicant: General Electric CompanyInventors: Naseer Shaik, Pritesh Kasliwal, Mohammed Afzal Khan
-
Patent number: 8501733Abstract: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: July 24, 2009Date of Patent: August 6, 2013Assignee: Eisai R&D Management Co., Ltd.Inventors: Takafumi Motoki, Toshihiko Kaneko, Noboru Yamamoto, Afzal Khan
-
Patent number: 8178552Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: GrantFiled: August 5, 2009Date of Patent: May 15, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Afzal Khan, Gurpreet Singh Bhatia, Christopher Neil Farthing
-
Publication number: 20120094984Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: December 21, 2011Publication date: April 19, 2012Applicant: EISAI R&D MANAGEMENT CO., LTD.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Patent number: 8158620Abstract: A compound represented by the general formula: or a pharmaceutically acceptable salt thereof or a solvate thereof, wherein Ring A is a C6-14 aryl group or the like, L is —NReCO— or the like (wherein Re is a hydrogen atom or the like), Ring B is a C6-14 aryl group or the like, X is a C1-3 alkylene group or the like, Y is a single bond or the like, Z is a C1-3 alkylene group or the like, R1 and R2 are each independently a hydrogen atom or the like, and R3, R4, R5 and R6 are independently a hydrogen atom, a halogen atom or the like, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: GrantFiled: January 16, 2009Date of Patent: April 17, 2012Assignee: Eisai R&D Management Co., Ltd.Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20110152253Abstract: A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof, has an A? production inhibitory effect or a BACE1 inhibitory effect and is useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by A? and typified by Alzheimer-type dementia.Type: ApplicationFiled: July 24, 2009Publication date: June 23, 2011Applicant: Eisai R&D Management Co., LtdInventors: Takafumi Motoki, Toshihiko Kaneko, Noboru Yamamoto, Afzal Khan
-
Patent number: 7951802Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: GrantFiled: August 5, 2009Date of Patent: May 31, 2011Assignee: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel Graczyk, Paschalis Dimopoulos, Christopher Neil Farthing, Gurpreet Singh Bhatia, Afzal Khan
-
Publication number: 20100317850Abstract: Disclosed is a compound represented by General formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the compound or the pharmaceutically acceptable salt, which has an inhibitory activity of the production of A? or a BACE1-inhibiting activity, and is therefore useful as a prophylactic or therapeutic agent for A?-induced neurodegenerative diseases typified by Alzheimer-type dementia. Wherein the ring A represents a C6-14 aryl group or the like; L represents —NReCO— [wherein Re represents a hydrogen atom or the like] or the like; the ring B represents a C6-14 aryl group or the like; X represents a C1-3 alkylene group or the like; Y represents a single bond or the like; Z represents a C1-3 alkylene group or the like; R1 and R2 independently represent a hydrogen atom or the like; and R3, R4, R5 and R6 independently represent a hydrogen atom, a halogen atom or the like.Type: ApplicationFiled: January 16, 2009Publication date: December 16, 2010Inventors: Yuichi Suzuki, Takafumi Motoki, Toshihiko Kaneko, Mamoru Takaishi, Tasuku Ishida, Kunitoshi Takeda, Yoichi Kita, Noboru Yamamoto, Afzal Khan, Paschalis Dimopoulos
-
Publication number: 20100069354Abstract: The present invention provides a compound of formula (I); or a pharmaceutically acceptable salt thereof, the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the inhibition of c-Jun N-terminal kinase (JNK) activity and the use in medicine and particularly in the treatment of neurodegenerative disorders, inflammatory diseases and/or and autoimmune diseases. The invention also provides processes for the manufacture of said compounds of formula (I) or a pharmaceutically acceptable salt thereof and compositions containing them.Type: ApplicationFiled: August 5, 2009Publication date: March 18, 2010Applicant: Eisai R&D Management Co., Ltd.Inventors: Piotr Pawel GRACZYK, Paschalis DIMOPOULOS, Afzal KHAN, Gurpreet Singh BHATIA, Christopher Neil FARTHING